Celwise AB Uses ExOne 3D Printed Tooling to Transform Wood Fiber into Innovative, Single-Use Plastic Replacement
7.9.2021 15:30:00 EEST | Business Wire | Press release
The ExOne Company (Nasdaq: XONE), the global leader in industrial sand and metal 3D printers using binder jetting technology, is proud to announce that innovative molded fiber technology supplier, Celwise AB of Norrköping, Sweden, is using metal tools 3D printed by ExOne in 316L stainless steel for its patented method of transforming wood and other cellulose fibers into a wide range of eco-friendly packaging and products.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210907005199/en/
Celwise's innovative and sustainable molded fiber products, which replace single-use plastics, are shown in front of the X1 160Pro™ production metal 3D printer. A key part of Celwise’s patented production method for producing this all-new type of molded fiber product is uniquely featured metal tooling that can only be made with additive manufacturing, such as ExOne’s binder jetting technology. (Photo: Business Wire)
Invented, developed and patented over the past 10 years, Celwise technology aims to transform the paper and plastics industry with its innovation, which produces a water-resistant molded fiber product that looks and feels like a luxurious blend of wood and plastic. Celwise technology is enjoying rapid success, with adoption projects now underway with a wide range of global companies serving many industries, including consumer products, food and beverage, cosmetics, and electronics.
“Our planet needs this technology now,” said David Pierce, Inventor and Co-Owner of Celwise. “Our patented technology delivers a recyclable, renewable, and biodegradable product that can be manufactured faster and more affordably than traditional technologies. Advanced manufacturing approaches, which rely on 3D printed tooling from ExOne, are an important part of our process.”
“Celwise is demonstrating how new technologies such as binder jet 3D printing can help solve some of the world’s toughest problems,” said John Hartner, ExOne’s CEO. “We’re proud to collaborate with Celwise on delivering this important innovation.”
How it Works
Celwise’s patented process includes unique tooling and machines, as well as a novel process, to deliver its final product. Common cellulose fiber-based (paper) product manufacturing slowly removes water from cellulose fiber for molded products that must be coated for water resistance.
Celwise, however, rapidly removes water in a new process that enables cellulose fibers to re-bond with each other quickly, creating a new type of paper product that is strong, wood-like, and water-resistant.
What’s more, because a series of forming, transferring and pressing tools are 3D printed using ExOne binder jetting technology, the process gives Celwise even more design freedom to develop their client’s products.
ExOne’s binder jet 3D printing transforms powdered materials — metal, sand or ceramic — into highly dense and functional precision parts at high speeds. An industrial printhead selectively deposits a binder into a bed of powder particles creating a solid part one thin layer at a time, similar to printing on sheets of paper.
When printing metals, such as the Celwise tools, the final bound metal part must be sintered in a furnace to fuse the particles together into a solid object. Binder jet 3D printing technology is viewed as a desirable and sustainable production method, largely because of its high speed, low waste and cost, as well as material flexibility.
ExOne is now providing prototype and production tools to Celwise specifications. While other metal 3D printing processes can produce the types of tools required by Celwise, Pierce estimates that ExOne binder jetting technology delivers a 20% time savings over those processes as well as a cost savings of 30-40%.
About ExOne
ExOne (Nasdaq: XONE) is the pioneer and global leader in binder jet 3D printing technology. Since 1995, we’ve been on a mission to deliver powerful 3D printers that solve the toughest problems and enable world-changing innovations. Our 3D printing systems quickly transform powder materials — including metals, ceramics, composites and sand — into precision parts, metalcasting molds and cores, and innovative tooling solutions. Industrial customers use our technology to save time and money, reduce waste, improve their manufacturing flexibility, and deliver designs and products that were once impossible. As home to the world’s leading team of binder jetting experts, ExOne also provides specialized 3D printing services, including on-demand production of mission-critical parts, as well as engineering and design consulting. Learn more about ExOne at www.exone.com or on Twitter at @ExOneCo. We invite you to join with us to #MakeMetalGreen™.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005199/en/
Contact information
Sarah Webster
Chief Marketing Officer
724.516.2336
sarah.webster@exone.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enhertu ® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer27.10.2026 09:30:00 EET | Press release
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. In DESTINY-Breast05, Enhertu significantly reduced the risk of in
Avanzanite Bioscience Expands UK Presence and Appoints Sarah O’Connell as Country Manager27.10.2026 09:00:00 EET | Press release
Avanzanite Bioscience B.V., a European pharmaceutical company focused on rare diseases, today announced the expansion of its United Kingdom (UK) presence and the appointment of Sarah O’Connell as UK Country Manager. The move strengthens Avanzanite’s long-term commitment to the UK and its ability to help eligible patients access innovative rare disease medicines. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027035012/en/ Sarah O'Connell, Country Manager, UK, Avanzanite Bioscience “The UK is essential to our ambition of building Avanzanite into a European rare disease champion. We feel a deep and lasting connection to this market and there is no European reach without the UK,” said Adam Plich, co-founder and CEO, Avanzanite Bioscience. “At a time when parts of the life sciences sector are reassessing their investment and presence in the UK, we are choosing to commit and build for the long term. With Sarah’s extensive rare
LTM Secures Strategic Engagement with a Global Banking and Financial Services Firm27.10.2026 06:30:00 EET | Press release
LTM, the Business Creativity partner to the world's largest enterprises, has secured a strategic engagement with a large global banking and financial services firm, further strengthening its position as a trusted technology and transformation partner to leading financial institutions. This two-year engagement is already underway with an option to extend for an additional year and has a potential value of up to USD 100 million. The engagement reflects the continued expansion of LTM’s relationship with the client and its growing role in advancing strategic technology programmes and supporting supplier consolidation initiatives across the organization. Under the agreement, LTM will serve as a preferred partner driving the consolidation and delivery of strategic technology requirements across key wealth, personal banking, and global functions. The engagement will leverage LTM’s deep banking-domain expertise, engineering excellence, and global delivery capabilities to support the client’s t
DDN Selected to Modernize Research Data Infrastructure at UNSW Sydney26.10.2026 23:30:00 EET | Press release
DDN, the global leader in AI and data intelligence solutions, today announced that UNSW Sydney has selected DDN to deliver a new research data storage environment as part of the university’s Research Data Experience (RDE) program. Working with Australian software company Arcitecta, DDN will combine its EXAScaler parallel file system with Arcitecta’s Mediaflux® data management platform to help researchers spend less time managing data and more time using it. Following an extensive 18-month evaluation, UNSW selected an integrated approach that will replace 11 legacy storage systems with a coordinated environment for high-performance storage and enterprise data management. The decision reflects a broader challenge facing research-intensive institutions: how to support rapidly expanding scientific datasets while simplifying infrastructure, improving data accessibility and managing long-term costs. Built for data-intensive research, high-performance computing and AI workloads, DDN EXAScaler
Agent Assurance by TestMu AI Is Now Generally Available, Letting Teams Test What Their AI Agents Actually Change26.10.2026 17:15:00 EET | Press release
TestMu AI (formerly LambdaTest), the world's first Agentic AI-powered Quality Engineering platform, today announced the general availability of Agent Assurance. Agent Assurance tests AI agents that take actions, such as calling tools, writing files, and changing records, by checking what a run actually changed rather than what the agent says it did. Any team can now create a TestMu AI account and run it against its own agent without booking a demo first. Agent Assurance launched on August 17, 2026, behind a waitlist and a guided onboarding session. Since then, Rook, the CLI that runs Agent Assurance, has shipped a steady run of releases, shaped by feedback from early teams. Agent evaluation has mostly graded the final reply, and that reply can be wrong about the agent's own work. In CXBench, a benchmark of LLM agents in regulated customer-experience workflows published in October 2026, 80.1% of runs that reached the right outcome still failed the process checks, and only 13.8% passed b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
